文献速递湿疹皮炎与荨麻疹

度普利尤单抗对比传统免疫调节剂降低儿童特应性皮炎患者特应性进程风险:基于人群的队列研究

Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study.
PubMed 文献 · J Am Acad Dermatol · 2024-06-14

本研究基于TriNetX美国协作网络(2011-2024)的回顾性队列数据,纳入≤18岁特应性皮炎患者,比较新处方度普利尤单抗(DUPI队列)与传统免疫调节剂(CONV队列)对特应性进程(新发哮喘或过敏性鼻炎)的影响。经1:1倾向评分匹配后,每组2192例,DUPI队列3年特应性进程累积发生率低于CONV队列(20.09% vs 27.22%,P < .001),风险显著降低(HR 0.68,95%CI 0.55-0.83)。

要点

  • 度普利尤单抗组3年特应性进程累积发生率为20.09%,低于传统治疗组的27.22%。
  • 年轻患者使用度普利尤单抗对特应性进程和哮喘的风险降低更明显。

核心结论

  • 在儿童特应性皮炎患者中,与传统免疫调节剂相比,度普利尤单抗与特应性进程风险降低相关。

研究设计与样本

  • 回顾性队列研究,使用TriNetX美国协作网络2011-2024年数据,纳入≤18岁特应性皮炎患者,分为度普利尤单抗新处方组和传统免疫调节剂组,经1:1倾向评分匹配后每组2192例。

主要发现

  • 度普利尤单抗组3年特应性进程累积发生率为20.09%,传统治疗组为27.22%(P < .001)。
  • 度普利尤单抗组特应性进程风险显著降低(HR 0.68,95%CI 0.55-0.83)。
  • 度普利尤单抗组哮喘风险降低(HR 0.60,95%CI 0.45-0.81),过敏性鼻炎风险降低(HR 0.69,95%CI 0.54-0.88)。
  • 年轻患者使用度普利尤单抗对特应性进程和哮喘的风险降低更明显,而过敏性鼻炎呈现相反年龄相关模式。

临床怎么用

  • 对于儿童特应性皮炎患者,度普利尤单抗可能有助于降低特应性进程(哮喘和过敏性鼻炎)风险,尤其年轻患者可能获益更明显。

局限性

  • 观察性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab effectively treats atopic dermatitis (AD); however, its role in halting the atopic march remains uncertain. OBJECTIVE: To investigate dupilumab's effect on atopic march in pediatric AD patients versus conventional immunomodulators. METHODS: This retrospective cohort study utilized data from the TriNetX US Collaborative Network (2011-2024). Pediatric AD patients (≤18 years) were categorized into DUPI-cohort (newly prescribed dupilumab) or CONV-cohort (prescribed conventional immunomodulators without dupilumab). After 1:1 propensity-score matching, we analyzed atopic march progression, defined by the incident asthma or allergic rhinitis (AR). Cumulative incidence was plotted using Kaplan-Meier, with risk assessment via Cox regression. RESULTS: The study included 2192 patients in each cohort. The 3-year cumulative incidence of atopic march progression was lower in the DUPI-cohort than the CONV-cohort (20.09% vs 27.22%; P < .001). The DUPI-cohort demonstrated significant risk reduction in atopic march progression (hazard ratio [HR] 0.68, 95% CI 0.55-0.83), individual asthma (HR 0.60, 0.45-0.81), and individual AR (HR 0.69, 0.54-0.88). Younger patients on dupilumab exhibited a greater risk reduction for atopic march progression and individual asthma, contrasting with the opposite age-related pattern for individual AR. LIMITATIONS: Observational study. CONCLUSION: Among pediatric AD patients, dupilumab was associated with reduced risk of atopic march progression compared with conventional therapies.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Lin TL, Fan YH, Fan KS, et al. Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study. J Am Acad Dermatol. 2024. PMID: 38878041. doi:10.1016/j.jaad.2024.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。